Upgrade to SI Premium - Free Trial

Spyre Therapeutics (SYRE)

73.65 -4.83 (6.15%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Spyre Therapeutics Announces Grants of Inducement Awards June 5, 2026 4:01 PM - Globe NewsWire Spyre (SYRE) PT Raised to $115 at Deutsche Bank June 4, 2026 4:10 AM - StreetInsider Form 4 Spyre Therapeutics, Inc. For: Jun 03 Filed by: Sloan Sheldon June 3, 2026 9:32 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Turtle Cameron June 3, 2026 9:31 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Jun 01 Filed by: Burrows Scott L June 3, 2026 9:31 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon June 3, 2026 4:28 PM - SEC Filing Spyre completes enrollment in SKYWAY trial for anti-TL1A therapy SPY072 June 3, 2026 8:03 AM - StreetInsider Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA June 3, 2026 8:00 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: May 29 June 1, 2026 4:03 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Kiselak Tomas May 29, 2026 5:58 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Albers Jeffrey W. May 29, 2026 5:56 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: HENDERSON MICHAEL THOMAS May 29, 2026 5:56 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Stelzer Laurie May 29, 2026 5:55 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: McKenna Mark C. May 29, 2026 5:55 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 27 Filed by: Milligan Sandra May 29, 2026 5:55 PM - SEC Filing Form 8-K Spyre Therapeutics, Inc. For: May 27 May 29, 2026 4:46 PM - SEC Filing Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation May 28, 2026 8:35 AM - StreetInsider Spyre Therapeutics to Participate in Upcoming June Investor Conferences May 26, 2026 4:10 PM - StreetInsider Form 4 Spyre Therapeutics, Inc. For: May 08 Filed by: HENDERSON MICHAEL THOMAS May 8, 2026 9:32 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: HENDERSON MICHAEL THOMAS May 8, 2026 4:23 PM - SEC Filing Spyre (SYRE) PT Raised to $107 at Stifel May 5, 2026 4:26 PM - StreetInsider Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c May 5, 2026 10:20 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: May 05 May 5, 2026 8:05 AM - SEC Filing Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 May 5, 2026 8:01 AM - SEC Filing Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 5, 2026 8:00 AM - Globe NewsWire Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Burrows Scott L May 1, 2026 9:35 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Sloan Sheldon May 1, 2026 9:35 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Turtle Cameron May 1, 2026 9:34 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon May 1, 2026 4:45 PM - SEC Filing Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L May 1, 2026 4:45 PM - SEC Filing Spyre Therapeutics Announces Grants of Inducement Awards May 1, 2026 4:28 PM - Globe NewsWire Form SCHEDULE 13G Spyre Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC April 22, 2026 4:00 PM - SEC Filing Form SCHEDULE 13D/A Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC April 20, 2026 6:00 PM - SEC Filing Form 8-K Spyre Therapeutics, Inc. For: Apr 14 April 16, 2026 4:16 PM - SEC Filing Spyre Therapeutics closes $463.5 million public offering April 16, 2026 4:15 PM - StreetInsider Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million April 16, 2026 4:15 PM - StreetInsider Form 424B5 Spyre Therapeutics, Inc. April 16, 2026 6:02 AM - SEC Filing Spyre Therapeutics prices $403 million stock offering at $62 per share April 14, 2026 10:38 PM - StreetInsider Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock April 14, 2026 10:38 PM - Globe NewsWire Spyre (SYRE) PT Raised to $90 at Baird April 14, 2026 7:23 AM - StreetInsider Spyre (SYRE) PT Raised to $90 at Wells Fargo April 14, 2026 7:02 AM - StreetInsider Form 424B5 Spyre Therapeutics, Inc. April 13, 2026 5:26 PM - SEC Filing Spyre Therapeutics announces $300 million public stock offering April 13, 2026 4:47 PM - StreetInsider Spyre Therapeutics Announces Proposed Public Offering of its Common Stock April 13, 2026 4:46 PM - Globe NewsWire Form 8-K Spyre Therapeutics, Inc. For: Apr 13 April 13, 2026 4:29 PM - SEC Filing Raymond James Starts Spyre (SYRE) at Strong Buy, $80 PT April 13, 2026 4:06 PM - StreetInsider Spyre (SYRE) PT Raised to $84 at Mizuho April 13, 2026 3:10 PM - StreetInsider Syre Therapeutics (SYPR) PT Raised to $106 at Leerink Partners, 'initial SKYLINE results represent best-case data for SPY001' April 13, 2026 2:20 PM - StreetInsider Spyre (SYRE) PT Raised to $85 at Jefferies April 13, 2026 12:37 PM - StreetInsider Spyre (SYRE) PT Raised to $98 at BTIG April 13, 2026 11:24 AM - StreetInsider Spyre (SYRE) PT Raised to $80 at Wedbush April 13, 2026 10:38 AM - StreetInsider Stifel on Spyre (SYRE): 'solid foundation for combos where we expect synergistic activity' April 13, 2026 8:45 AM - StreetInsider Goldman Sachs on Spyre (SYRE): 'Initial SPY001 efficacy data bolsters confidence into remaining data readouts later this year' April 13, 2026 8:26 AM - StreetInsider Leerink on Spyre (SYRE): 'one of our Top Picks for 2026' April 13, 2026 8:21 AM - StreetInsider TD Cowen on Spyre (SYRE): 'we expect these data to further raise the ceiling for Spyre's future combos' April 13, 2026 7:57 AM - StreetInsider Mizuho on Spyre (SYRE): 'We see these results as an extremely favorable outcome' April 13, 2026 7:54 AM - StreetInsider Form 8-K Spyre Therapeutics, Inc. For: Apr 13 April 13, 2026 7:47 AM - SEC Filing Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news' April 13, 2026 7:46 AM - StreetInsider Spyre reports positive trial results for ulcerative colitis drug SPY001 April 13, 2026 7:00 AM - StreetInsider Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients April 13, 2026 7:00 AM - StreetInsider Spyre Therapeutics (SYRE) Halted, News Pending April 13, 2026 6:56 AM - StreetInsider Form ARS Spyre Therapeutics, Inc. For: Dec 31 April 10, 2026 4:14 PM - SEC Filing Form DEFA14A Spyre Therapeutics, Inc. April 10, 2026 4:05 PM - SEC Filing Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 April 10, 2026 4:05 PM - StreetInsider Form DEF 14A Spyre Therapeutics, Inc. For: May 27 April 10, 2026 4:02 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Apr 01 Filed by: Turtle Cameron April 3, 2026 9:31 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Apr 01 Filed by: Sloan Sheldon April 3, 2026 9:30 PM - SEC Filing Form 4 Spyre Therapeutics, Inc. For: Apr 01 Filed by: Burrows Scott L April 3, 2026 9:29 PM - SEC Filing Spyre Therapeutics Announces Grants of Inducement Awards April 3, 2026 4:01 PM - Globe NewsWire Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon April 1, 2026 4:39 PM - SEC Filing BTIG Reiterates Buy Rating on Spyre (SYRE) March 31, 2026 5:18 AM - StreetInsider Form SCHEDULE 13G/A Spyre Therapeutics, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 1:18 PM - SEC Filing Spyre (SYRE) PT Raised to $92 at Stifel March 17, 2026 4:20 PM - StreetInsider Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution' March 16, 2026 11:33 AM - StreetInsider Guggenheim on Spyre Therapeutics (SYRE): 'remains one of our Top 2026 Picks' March 16, 2026 10:39 AM - StreetInsider Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 March 16, 2026 8:00 AM - StreetInsider Full Article List